CLEARSIDE BIOMEDICAL, INC. (NASDAQ:CLSD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 3, 2017, Derek Yoon provided notice to the board of directors (the “Board”) of Clearside Biomedical, Inc. (the “Company”) of his decision to resign from the Board and the Company’s Audit Committee, effective as of August 8, 2017. Mr. Yoon’s decision to resign was not the result of any disagreement with the Company.

Also effective on August 8, 2017, the Board appointed George Lasezkay to serve as a director of the Company and as a member of the Company’s Audit Committee.Dr. Lasezkay will serve as a Class III director whose term will expire at the 2019 annual meeting of stockholders. There is no arrangement or understanding between Dr. Lasezkay and any other person to which he was selected as a director of the Company, and there is no family relationship between Dr. Lasezkay and any of the Company’s other directors or executive officers.The Company is not aware of any transaction involving Dr. Lasezkay requiring disclosure under Item 404(a) of Regulation S-K. Additional information about Dr. Lasezkay is set forth below.

George Lasezkay, age 65, has served as an Adjunct Professor, Pharmaceutical Law and Policy at the University of San Diego School of Law since January 2013.He previously served as Executive Vice President and General Counsel of Acucela Inc., a pharmaceutical company, from August 2015 to July 2016.Prior to Acucela, Dr. Lasezkay served as President of Horizon Pharma Consulting Group from 2005 to December 2015.Dr. Lasezkay received a B.S. and Pharm.D. from the University of Buffalo, a J.D. from the University of Southern California Gould School of Law and a Certificate, Dispute Resolution from Pepperdine University School of Law.

In accordance with the Company’s compensation policy for non-employee directors, upon his commencement of service as a director, Dr. Lasezkay will be granted a nonqualified stock option to purchase 22,500 shares of the Company’s common stock.The stock option will have an exercise price per share equal the closing price of the Company’s common stock on the date of grant.This option will vest and become exercisable in 36 equal monthly installments subject to Dr. Lasezkay’s Continuous Service (as defined in the Company’s 2016 Equity Incentive Plan) through such vesting dates.Additionally, Dr. Lasezkay will be entitled to receive a $40,000 annual retainer for his service as director and a $8,000 annual retainer for his service on the Audit Committee.At each annual stockholder meeting following which Dr. Lasezkay’s term as a director continues, Dr. Lasezkay will be entitled to receive an additional nonqualified stock option to purchase 11,250 shares of the Company’s common stock, which option will vest in full and become exercisable on the earlier of the date immediately prior to the next annual stockholder meeting or 12 months following the date of grant.Dr. Lasezkay has also entered into the Company’s standard form of indemnification agreement.

Item 7.01 Regulation FD Disclosure.

On August 8, 2017, the Company issued a press release announcing the resignation of Mr. Yoon and the appointment of Dr. Lasezkay. A copy of this press release is furnished herewith as Exhibit99.1 to this Current Report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Exhibits.

(d)Exhibits

Clearside Biomedical, Inc. Exhibit
EX-99.1 2 clsd-ex991_6.htm EX-99.1 BOARD ANNOUNCEMENT clsd-ex991_6.htm Exhibit 99.1   Clearside Biomedical,…
To view the full exhibit click here

About CLEARSIDE BIOMEDICAL, INC. (NASDAQ:CLSD)

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.